|
Pegvisomant
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | |
| ATC code | H01 |
| PubChem | ? |
| Chemical data | |
| Formula | C990H1532N262O300S7 |
| Mol. mass | 22129.0 g/mol (unpegylated) |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pegvisomant (trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly.[1]
References
- ^ Schreiber, I; Buchfelder M, Droste M et al. (January 2007). "Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study". European Journal of Endocrinology 156 (1): 75–82. doi:. PMID 17218728. http://www.eje-online.org/cgi/content/full/156/1/75?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&author1=Schreiber&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&volume=156&resourcetype=HWCIT.
|
|||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
